Articles
August 11, 2018
New Kind of Drug, Silencing Genes, Gets FDA Approval [Wall Street Journal]
The following article appeared in The Wall Street Journal on August 10, 2018...
"New Kind of Drug, Silencing Genes, Gets FDA Approval"...
Read More ›
August 3, 2018
Barry Greene Named to PharmaVoice 100 "For Being an RNAi Champion"
Alnylam President Barry Greene has been named to the PharmaVoice 100 for 2018. Barry was selected "for being an RNAi champion."
Read More ›
June 19, 2018
Guest Post: Finding Hope in a Potential New Class of Medicines
Amyloidosis first entered my husband’s life and my life in the mid-1990s, when we began to care for my uncle who had amyloidosis, a time I call the “dark ages.
Read More ›
June 19, 2018
Guest Post: The Heroes Among Us
For many of us, it’s unimaginable to think of a daily life filled with intractable pain. It’s also hard to imagine caring for someone in pain of that...
Read More ›
April 30, 2018
Hunting for Targets: Bringing RNAi to Humans
Evolution is a powerful force, and Mother Nature is often a great source of inspiration for drug hunters like me. If you look at the history of successful...
Read More ›
April 30, 2018
Building to Scale: Raising RNAi Therapeutics From Infancy
When I joined Alnylam in 2004, one of our early challenges was figuring out how to manufacture and deliver RNAi therapeutics for our clinical trials. The...
Read More ›
February 28, 2018
Harnessing the Power of RNAi™: Pushing Through the Challenges and Setbacks
I am an organic chemist, and what keeps me going after 3 decades working in the field of oligonucleotides is transforming complex chemistry into medicines...
Read More ›
February 28, 2018
A Note from Nicole Boice of Global Genes: Hope Is on the Horizon
On this Rare Disease Day—and as is the case each year on February 28—I’m reminded of why I founded Global Genes nearly a decade ago. At that time, I was just...
Read More ›
February 28, 2018
RNAi Therapeutics: From Eureka! Moment to a Potential New Class of Medicines
How far science and technology have come! At Alnylam, we believe we’re on the verge of a landmark moment in medicine and I can’t help but express my...
Read More ›
January 18, 2018
Alnylam Co-Founds UK Biobank Exome Sequencing Consortium (UKB-ESC)
Alnylam and partners announced an agreement with the UK Biobank to form the UK Biobank Exome Sequencing Consortium (UKB-ESC), to sequence all 500,000 exomes...
Read More ›
